Characterization of antibody reactivity to human T-cell lymphotropic virus types I and II using immunoblot and radioimmunoprecipitation assays

We have characterized the immunoreactivity to human T-cell lymphotropic virus type I (HTLV-I) among 26,983 persons of various seroprevalence groups by using enzyme immunoassay, immunoblot (IB), and radioimmunoprecipitation assays (RIPA) in accordance with Public Health Service recommended guidelines for the interpretation of serologic test results for HTLV-I infection. IB-indeterminate serum specimens (n = 178) were reactive to HTLV-I gag proteins, and no serum contained only env reactivity. Overall, RIPA resolved 40% of IB-indeterminate serum samples; however, the probability that RIPA would confirm IB-indeterminate samples depended on the seroprevalence of the population tested. HTLV-I gag p19-only reactivity on IB was not a reliable marker of HTLV-I infection, while gag p24 reactivity on IB was clearly associated with positive seroreactive specimens. IB and RIPA tests did not clearly distinguish between HTLV-I and HTLV-II seroreactivities. These data emphasize that patterns of immunoreactivity to HTLV-I antigens are dependent upon the seroprevalence of the risk groups tested. In addition, RIPA detected antibodies to env proteins present in low titer in a substantial number of IB gag-only reactive sera and resolved the HTLV-I antibody status of these sera.

[1]  J. Epstein,et al.  Serological confirmation of human T-lymphotropic virus type I infection in healthy blood and plasma donors. , 1989, Blood.

[2]  J. Zack,et al.  High rate of HTLV-II infection in seropositive i.v. drug abusers in New Orleans. , 1989, Science.

[3]  B. Haynes,et al.  Mapping of immunogenic regions of human T cell leukemia virus type I (HTLV-I) gp46 and gp21 envelope glycoproteins with env-encoded synthetic peptides and a monoclonal antibody to gp46. , 1989, Journal of immunology.

[4]  L. Ratner,et al.  Leukemias Associated with Human T‐Cell Lymphotropic Virus Type I in a Non‐Endemic Region , 1988, Medicine.

[5]  W. Blattner,et al.  Licensure of screening tests for antibody to human T-lymphotropic virus type I. , 1988, MMWR. Morbidity and mortality weekly report.

[6]  D. Slamon,et al.  Seroprevalence and epidemiological correlates of HTLV-I infection in U.S. blood donors. , 1988, Science.

[7]  京都大学ウイルス研究所,et al.  Adult T-cell leukemia virus , 1988 .

[8]  S. Weiss,et al.  Prevalence of antibodies to HTLV-I, -II, and -III in intravenous drug abusers from an AIDS endemic region. , 1986, JAMA.

[9]  B. Haynes,et al.  Monoclonal antibodies reactive with human T cell lymphotropic virusI (HTLVI) p19 internal core protein: cross-reactivity with normal tissues and differential reactivity with HTLV types I and II. , 1985, Journal of immunology.

[10]  K. Okochi,et al.  A Retrospective Study on Transmission of Adult T Cell Leukemia Virus by Blood Transfusion: Seroconversion in Recipients , 1984, Vox sanguinis.

[11]  B. Haynes,et al.  Monoclonal antibodies against human T cell leukemia-lymphoma virus (HTLV) p24 internal core protein. Use as diagnostic probes and cellular localization of HTLV , 1984, The Journal of experimental medicine.

[12]  R. Gallo,et al.  Antibodies against three purified proteins of the human type C retrovirus, human T-cell leukemia-lymphoma virus, in adult T-cell leukemia-lymphoma patients and healthy Blacks from the Caribbean. , 1983, Cancer research.

[13]  M. Kikuchi,et al.  Antibodies to adult t‐cell leukemia‐virus‐associated antigen (atla) in sera from patients with atl and controls in japan: A nation‐wide sero‐epidemiologic study , 1982, International journal of cancer.

[14]  Y. Ohtsuki,et al.  Type C virus particles in a cord T-cell line derived by co-cultivating normal human cord leukocytes and human leukaemic T cells , 1981, Nature.

[15]  John D. Minna,et al.  Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma , 1980, Proceedings of the National Academy of Sciences.

[16]  N. Bersch,et al.  Production of erythroid-potentiating activity by a human T-lymphoblast cell line. , 1980, Proceedings of the National Academy of Sciences of the United States of America.